EDAP TMS S.A. to Release 2007 Second Quarter Results
17 August 2007 - 8:06AM
PR Newswire (US)
LYON, France, Aug. 16 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP), the global leader in High Intensity Focused
Ultrasound (HIFU) treatment of prostate cancer and the
international leader in the development, production, and
distribution of a wide portfolio of minimally invasive medical
devices primarily for the treatment of urological diseases will
release its second quarter 2007 financial results Thursday, August
30, 2007 before the market open. Management will host a conference
call the same day, at noon Eastern Time, 6:00 p.m. Paris Time.
Interested investors may join the call live by dialing (866)
463-5401 from the United States or +1 (212) 457-9857 from
international locations and entering PIN code 762482#. Investors
may also listen to the live call online at
http://www.edap-tms.com/. Investors unable to join the call can
access a playback of the conference call by telephone or online. To
access the replay, please dial (866) 439-4554 or +1 (212) 457-9844
and using access code 334818# beginning one hour after the end of
the call until March 22, 2007, or visit the company's Web site at
http://www.edap-tms.com/. About EDAP TMS S.A. EDAP TMS S.A.
develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU)
treatment of localized prostate cancer. HIFU treatment is shown to
be a minimally invasive and effective treatment option with a low
occurrence of side effects. Ablatherm-HIFU is generally recommended
for patients with localized prostate cancer (stages T1-T2) who are
not candidates for surgery or who prefer an alternative option, or
for patients who failed radiotherapy treatment. The company is also
developing this technology for the potential treatment of certain
other types of tumors. EDAP TMS S.A. also produces and
commercializes medical equipment for treatment of urinary tract
stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more
information on the Company, contact Magnolia Investor Relations at
(972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4
78 26 40 46 or see the Company's Web sites at
http://www.edap-tms.com/ and http://www.hifu-planet.com/. To sign
up for alerts please visit:
http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0 In
addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties.
These include statements regarding the Company's growth and
expansion plans. Such statements are based on management's current
expectations and are subject to a number of uncertainties and risks
that could cause actual results to differ materially from those
described in these forward-looking statements. Factors that may
cause such a difference include, but are not limited to, those
described in the Company's filings with the Securities and Exchange
Commission. Ablatherm-HIFU treatment is in clinical trials but not
yet FDA approved or marketed in the United States. CONTACT: EDAP
TMS S.A. Magnolia Investor Relations Blandine Confort Matt Kreps
+33 4 78 26 40 46 972 801 4900 DATASOURCE: EDAP TMS S.A. CONTACT:
Blandine Confort of EDAP TMS S.A., +33 4 78 26 40 46; or Matt Kreps
of Magnolia Investor Relations, +1-972-801-4900 Web site:
http://www.edap-tms.com/ http://www.hifu-planet.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024